Test Code PGXQP Focused Pharmacogenomics Panel, Varies
Specimen Required
Patient Preparation: A previous hematopoietic stem cell transplant from an allogenic donor will interfere with testing. For information about testing patients who have received a hematopoietic stem cell transplant, call 800-533-1710.
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 4 days/Frozen 4 days
Additional Information:
1. Specimens are preferred to be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.
2. To ensure minimum volume and concentration of DNA is met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.
Specimen Type: Cord blood
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send cord blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated 4 days/Frozen 4 days
Additional Information:
1. Specimens are preferred to be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.
2. To ensure minimum volume and concentration of DNA is met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.
3. While a properly collected cord blood sample may not be at risk for maternal cell contamination, unanticipated complications may occur during collection. Therefore, maternal cell contamination studies are recommended to ensure the test results reflect that of the patient tested and are available at an additional charge. Order MATCC / Maternal Cell Contamination, Molecular Analysis, Varies on the maternal specimen.
Specimen Type: Saliva
Patient Preparation: Patient should not eat, drink, smoke, or chew gum 30 minutes prior to collection.
Supplies: Saliva Collection Kit (T786)
Specimen Volume: 2 Swabs
Collection Instructions: Collect and send specimen per kit instructions.
Specimen Stability Information: Ambient (preferred) 30 days/Refrigerated 30 days
Additional Information: Saliva specimens are acceptable but not recommended. Due to lower quantity/quality of DNA yielded from saliva, some aspects of the test may not perform as well as DNA extracted from a whole blood sample. When applicable, specific gene regions that were unable to be interrogated will be noted in the report. Alternatively, additional specimen may be required to complete testing.
Specimen Type: Extracted DNA
Container/Tube:
Preferred: Screw Cap Micro Tube, 2 mL with skirted conical base
Acceptable: Matrix tube, 1mL
Collection Instructions:
1. The preferred volume is at least 100 mcL at a concentration of 75 ng/mcL.
2. Include concentration and volume on tube.
Specimen Stability Information: Frozen (preferred) 1 year/Ambient/Refrigerated
Additional Information: DNA must be extracted in a CLIA-certified laboratory or equivalent and must be extracted from a specimen type listed as acceptable for this test (including applicable anticoagulants). Our laboratory has experience with Chemagic, Puregene, Autopure, MagnaPure, and EZ1 extraction platforms and cannot guarantee that all extraction methods are compatible with this test. If testing fails, one repeat will be attempted, and if unsuccessful, the test will be reported as failed and a charge will be applied. If applicable, specific gene regions that were unable to be interrogated due to DNA quality will be noted in the report.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Neurology Specialty Testing Client Test Request (T732)
-Therapeutics Test Request (T831)
-Cardiovascular Test Request (T724)
-Renal Diagnostics Test Request (T830)
Useful For
Preemptive or reactive genotyping of patients for pharmacogenomic purposes
Providing an assessment for genes with strong drug-gene associations
Assisting in the management of patients with complex medication regimens
Testing Algorithm
If a specimen requires follow-up for CYP2D6, then reflex testing will be performed as appropriate at an additional charge.
For cord blood specimens, maternal cell contamination testing may be performed at an additional charge.
For more information see CYP2D6 Comprehensive Cascade Testing Algorithm.
Special Instructions
Method Name
Real Time Polymerase Chain Reaction (RT-PCR) with Allelic Discrimination Analysis/PCR followed by DNA Sequencing, when appropriate
Reporting Name
Focused Pharmacogenomics Panel, VSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Varies | Varies |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Varies
Report Available
3 to 14 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
0029U
0071U (if appropriate)
0072U (if appropriate)
0073U (if appropriate)
0074U (if appropriate)
0075U (if appropriate)
0076U (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PGXQP | Focused Pharmacogenomics Panel, V | 82118-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
610185 | CYP1A2 Genotype | 72884-0 |
610186 | CYP1A2 Phenotype | 94254-0 |
610187 | CYP2C19 Genotype | 57132-3 |
610188 | CYP2C19 Phenotype | 79714-2 |
610570 | CYP2C19 Activity Score | 104667-1 |
610189 | CYP2C9 Genotype | 46724-1 |
610190 | CYP2C9 Phenotype | 79716-7 |
610571 | CYP2C9 Activity Score | 104668-9 |
610191 | CYP2D6 Genotype | 40425-1 |
610192 | CYP2D6 Phenotype | 79715-9 |
610572 | CYP2D6 Activity Score | 104669-7 |
610193 | CYP3A4 Genotype | 81139-8 |
610194 | CYP3A4 Phenotype | 81145-5 |
610195 | CYP3A5 Genotype | 81140-6 |
610196 | CYP3A5 Phenotype | 79717-5 |
610197 | SLCO1B1 Genotype | 93412-5 |
610198 | SLCO1B1 Phenotype | 79722-5 |
610199 | Warfarin CYP2C9 Genotype | 46724-1 |
610201 | Warfarin VKORC1 Resistance Genotype | 50722-8 |
610200 | Warfarin VKORC1 Promoter Genotype | 50722-8 |
614000 | Warfarin CYP2C9 and VKORC1 Promoter Phenotype | 54451-0 |
610202 | Warfarin CYP4F2 *3 Genotype | 93197-2 |
610203 | Warfarin rs12777823 Genotype | 93198-0 |
610204 | Interpretation | 69047-9 |
610205 | Additional Information | 48767-8 |
610206 | Method | 85069-3 |
610207 | Disclaimer | 62364-5 |
610208 | Reviewed by | 18771-6 |